Drug intelligence / Profile preview

6-(methylsulfinyl)hexyl isothiocyanate

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

6-(methylsulfinyl)hexyl isothiocyanate (6-MITC) is a bioactive small molecule isothiocyanate derived from the wasabi plant (*Eutrema japonicum*). It is recognized for its potent anti-inflammatory, antioxidant, and anti-tumor properties. In preclinical oncology models, 6-MITC has demonstrated the ability to suppress the proliferation of various cancer cell lines, including endometrial carcinoma, by inducing apoptosis through the activation of cleaved-caspase 3 and the downregulation of BCL2. Furthermore, 6-MITC has been shown to enhance natural killer (NK) cell activity and increase the sensitivity of tumor cells to chemotherapeutic agents such as cisplatin.

Other names: 6-methylsulfinylhexyl isothiocyanateWasabi isothiocyanate

Targets

CASP3 (Caspase-3)

Beyond the preview

Go deeper on 6-(methylsulfinyl)hexyl isothiocyanate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6-(methylsulfinyl)hexyl isothiocyanate.

Explore the full profile